CJC-1295 / Ipamorelin
Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
Both compounds have pharmacology data in healthy adults showing increased endogenous GH pulses without affecting prolactin or cortisol much. Some PK/PD trials are published.
What's still experimental
Outcome trials (body composition, recovery, longevity) are sparse and mostly small. Long-term safety of repeated GH stimulation is not well established.
Anecdotal / community reports
Body-composition and sleep-quality reports are common; many users overlook baseline lifestyle and training.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
Live research
Updated hourly · sourced from PubMed + ClinicalTrials.govClinical trials (ClinicalTrials.gov)
- A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityTERMINATEDNCT00267527 · PHASE2 · n=120 · 2005-12
- Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionCOMPLETEDNCT01280344 · PHASE2 · n=320 · 2011-04
- Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusCOMPLETEDNCT00672074 · PHASE2 · n=117 · 2008-04
Known risks
Carries risks similar to elevated GH (insulin resistance, edema). Not approved for general use.
Reported side effects
Water retention, injection-site irritation, headaches.
What requires medical supervision
Carries risks consistent with elevated GH (insulin resistance, edema, joint discomfort). Should be supervised; baseline IGF-1 and glycemic monitoring are reasonable.
Questions for your clinician
- Should we baseline IGF-1, fasting glucose, and HbA1c?
- How long is one cycle and how do we de-escalate?
- What signs of insulin resistance should I watch for?